Discovery of quinazolin-4(3H)-one derivatives as novel AChE inhibitors with anti-inflammatory activities.

[1]  W. Sippl,et al.  Discovery of Potent Cholinesterase Inhibition-Based Multi-Target-Directed Lead Compounds for Synaptoprotection in Alzheimer's Disease. , 2022, Journal of medicinal chemistry.

[2]  T. Govindaraju,et al.  Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer's Disease. , 2022, Journal of medicinal chemistry.

[3]  A. Laghezza,et al.  Structure-based design of novel donepezil-like hybrids for a multi-target approach to the therapy of Alzheimer's disease. , 2022, European journal of medicinal chemistry.

[4]  D. Praticò,et al.  Beneficial effects of QTC-4-MeOBnE in an LPS-induced mouse model of depression and cognitive impairments: The role of blood-brain barrier permeability, NF-κB signaling, and microglial activation , 2021, Brain, Behavior, and Immunity.

[5]  Zhaogang Bian,et al.  Imidazolylacetophenone oxime-based multifunctional neuroprotective agents: Discovery and structure-activity relationships. , 2021, European journal of medicinal chemistry.

[6]  G. Rabinovici.  Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab. , 2021, The New England journal of medicine.

[7]  Lei Wu,et al.  Inflammation and tumor progression: signaling pathways and targeted intervention , 2021, Signal Transduction and Targeted Therapy.

[8]  Asher Mullard.  Controversial Alzheimer’s drug approval could affect other diseases , 2021, Nature.

[9]  A. Zawadzka,et al.  "Clicking" fragment leads to novel dual-binding cholinesterase inhibitors. , 2021, Bioorganic & medicinal chemistry.

[10]  J. P. S. Ferreira,et al.  Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR). , 2021, European journal of medicinal chemistry.

[11]  C. Glass,et al.  Monosodium Urate Crystals regulate a unique JNK-dependent macrophage metabolic and inflammatory response , 2021, bioRxiv.

[12]  M. Bartolini,et al.  Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer’s Disease , 2021, Journal of medicinal chemistry.

[13]  Haifang Xiao,et al.  Inhibitory activity and mechanism of trilobatin on tyrosinase: kinetics, interaction mechanism and molecular docking. , 2021, Food & function.

[14]  S. Prajapati,et al.  Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer's action: Design, synthesis, crystal structure and in-vitro biological evaluation. , 2021, European journal of medicinal chemistry.

[15]  Marine Peuchmaur,et al.  β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy. , 2021, Journal of medicinal chemistry.

[16]  Lun Ma,et al.  Comparative study of inhibition mechanisms of structurally different flavonoid compounds on α-glucosidase and synergistic effect with acarbose. , 2021, Food chemistry.

[17]  J. Hewitt,et al.  Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis , 2019, Cochrane Database of Systematic Reviews.

[18]  V. Andrisano,et al.  Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice. , 2020, Journal of medicinal chemistry.

[19]  V. Andrisano,et al.  Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer’s Disease Multitarget Drug Discovery? , 2020, Journal of medicinal chemistry.

[20]  C. Escande,et al.  A novel nitroalkene vitamin E analogue inhibits the NLRP3 inflammasome and protects against inflammation and glucose intolerance triggered by obesity , 2020, Redox biology.

[21]  S. Koh,et al.  Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes , 2020, Translational Neurodegeneration.

[22]  W. Wong.  Economic burden of Alzheimer disease and managed care considerations. , 2020, The American journal of managed care.

[23]  S. Rahman,et al.  Melatonin prevents neuroinflammation and relieves depression by attenuating autophagy impairment through FOXO3a regulation. , 2020, Journal of pineal research.

[24]  M. Colonna,et al.  Neuroinflammation and neurodegeneration in human brain at single-cell resolution , 2019, Nature Reviews Immunology.

[25]  L. Buée,et al.  NLRP3 inflammasome activation drives tau pathology , 2019, Nature.

[26]  Shengtao Xu,et al.  Multi-target design strategies for the improved treatment of Alzheimer's disease. , 2019, European journal of medicinal chemistry.

[27]  J. Cummings,et al.  Alzheimer's disease drug development pipeline: 2019 , 2019, Alzheimer's & dementia.

[28]  N. Ip,et al.  Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities. , 2018, ACS chemical neuroscience.

[29]  Xuan Li,et al.  Activation of AMPK inhibits inflammatory response during hypoxia and reoxygenation through modulating JNK-mediated NF-κB pathway. , 2018, Metabolism: clinical and experimental.

[30]  Norbert Benda,et al.  Precision pharmacology for Alzheimer's disease. , 2018, Pharmacological research.

[31]  M. Heneka,et al.  Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease , 2017, Nature.

[32]  Asher Mullard.  BACE inhibitor bust in Alzheimer trial , 2017, Nature Reviews Drug Discovery.

[33]  Stanislav Katina,et al.  Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial , 2017, The Lancet Neurology.

[34]  K. Blackburn,et al.  Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease. , 2017, The journal of prevention of Alzheimer's disease.

[35]  G. Núñez,et al.  Mechanism and Regulation of NLRP3 Inflammasome Activation. , 2016, Trends in biochemical sciences.

[36]  L. Abou-zeid,et al.  Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibitory activities and molecular docking studies of substituted 2-mercapto-4(3H)-quinazolinones. , 2016, European journal of medicinal chemistry.

[37]  M. Mohamed,et al.  Design, synthesis of 2,3-disubstitued 4(3H)-quinazolinone derivatives as anti-inflammatory and analgesic agents: COX-1/2 inhibitory activities and molecular docking studies. , 2016, Bioorganic & medicinal chemistry.

[38]  Paul Edison,et al.  Neuroinflammation in Alzheimer's disease: Current evidence and future directions , 2016, Alzheimer's & Dementia.

[39]  F. Geissmann,et al.  The development and maintenance of resident macrophages , 2015, Nature Immunology.

[40]  Jennifer Luebke,et al.  Depletion of microglia and inhibition of exosome synthesis halt tau propagation , 2015, Nature Neuroscience.

[41]  J. El Khoury,et al.  β-amyloid, microglia, and the inflammasome in Alzheimer’s disease , 2015, Seminars in Immunopathology.

[42]  M. Heneka,et al.  Innate immunity in Alzheimer's disease , 2015, Nature Immunology.

[43]  F. Fahrenholz,et al.  Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin , 2014, Neurology.

[44]  T. Rosenberry,et al.  Structures of human acetylcholinesterase bound to dihydrotanshinone I and territrem B show peripheral site flexibility. , 2013, ACS medicinal chemistry letters.

[45]  Arup K. Ghose,et al.  Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery , 2011, ACS chemical neuroscience.

[46]  Bin Wang,et al.  Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. , 2010, European journal of medicinal chemistry.

[47]  Qiaojun He,et al.  Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors. , 2009, Bioorganic & medicinal chemistry.

[48]  V. Morsch,et al.  Inhibition of two different cholinesterases by tacrine. , 2006, Chemico-biological interactions.